Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
6(75.0%)
Phase 2
2(25.0%)
8Total
Phase 1(6)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06704347Phase 1Not Yet Recruiting

Safety Study of XT-150 in Participants With ALS

Role: lead

NCT04124042Phase 2Completed

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

Role: lead

NCT05196919Phase 2Completed

Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

Role: lead

NCT04466410Phase 1Terminated

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain

Role: lead

NCT04841512Phase 1Withdrawn

Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

Role: lead

NCT03769662Phase 1Completed

Follow on Extension of XT-150-1-0201

Role: lead

NCT03477487Phase 1Completed

Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

Role: lead

NCT03282149Phase 1Completed

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

Role: lead

All 8 trials loaded